Business Wire - October 9, 2006

More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are expected to reach the market early stage therapies will be simplified by new products that will transform the market. For those with few treatment options left, new pipeline products will redefine late stage therapy.

Scope of this title:

- Discussion of the epidemiology dynamics of HIV in the seven major markets, as well as the changing unmet needs that result

- Assessment of late-phase clinical development compounds, competitors, and opinion leader comments on trial design

- Forecasted sales of drugs in the antiretroviral market for the next 10 years

- Examination of the emerging drug classes including Entry Inhibitors and Integrase Inhibitors

Highlights of this title:

- The increased use of antiretroviral agents has been accompanied by a rise in resistance to these drugs. Resistance generally falls into two categories: natural and acquired. The factors surrounding the development of HIV resistance are interrelated and include poor drug compliance, pharmacological factors, and direct molecular drug resistance.

- Atripla, approved in the US in July 2006, has been one of the greatest developments in HIV therapy. A combination of two class leaders, Truvada and Sustiva, the triple pill is the first to combine the components of HAART into a single pill formulation taken once daily. The author forecasts it to reach peak sales in excess of $2 billion.

- Integrase inhibitors MK-0518 and GS-9137 look to be the most promising candidates in the EI and others pipeline. Of the two, MK-0518 is the most advanced and looks set to dominate the salvage market.

Reasons to read this report:

- Understand key drivers in the antiretroviral market and predict the future performance of key compounds

- Explore the changing unmet needs of patients and clinical endpoints used in current trial design

- Evaluate forecasts for the antiretroviral market to 2015, taking into account key launch dates, patent expiries and generic incursion

Chapter Titles Include:

Chapter 1

Executive summary

Chapter 2

Patient potential

Chapter 3

R&D approach

Chapter 4

HIV pipeline analysis

Chapter 5

Nrti late-stage drug analysis & forecasts

Chapter 6

Nnrti late-stage drug analysis and forecasts

Chapter 7

Pi late-stage drug analysis and forecasts

Chapter 8

Ei and other late-stage drug analysis and forecasts

APPENDIX A

APPENDIX B

List of Tables

List of Figures

The Companies mentioned inside this report include:

- Elvucitabine

- Racivir

- AVX-754

- MIV-210

- Amdoxovir

- Reverset

- TMC125

- TMC278

- BILR355

- Calanolide A

- Capravirine

- GW-695634

- MIV-150

- Aptivus (tipranavir)

- Prezista (TMC114)

- Brecanavir

- Vicriviroc

- Maraviroc

- CXCR4 inhibitors

- AMD070

- TNX-355

- MK-0518

- GS-9137

- Bevirimat (PA-457)

- PRO-140

- TRI-999

- TRI-1144

For more information visit: http://www.researchandmarkets.com/reports/c43154

Source: Datamonitor

CONTACT: Research and Markets

Laura Wood

press@researchandmarkets.com

Fax: +353 1 684 99 77

SOURCE: Research and Markets
061009
BW061009

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .